CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV

Lelia H. Chaisson, Valeria Saraceni, Silvia Cohn, Dena Seabrook, Solange C. Cavalcante, Richard E. Chaisson, Jonathan E. Golub, Betina Durovni

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: In 2018, Brazilian guidelines changed to recommend tuberculosis (TB) preventive therapy for all people with HIV and a CD4 cell count 350 cells/μl or less, but only for those with a positive tuberculin skin test (TST) if CD4 cell count is than 350 cells/μl. We determined the potential effectiveness of CD4-based guidelines for TB testing and preventive therapy. DESIGN: Secondary analysis of the stepped-wedge, cluster-randomized THRio trial for isoniazid preventive therapy (IPT). METHODS: We analyzed data from 4114 newly registered patients with HIV in 29 clinics followed until TB diagnosis, death, or administrative censoring. We compared incidence rates of TB and TB/death between CD4, TST, IPT, and antiretroviral therapy categories. RESULTS: Initial CD4 cell count was 350 cells/μl or less in 2138 (52%) and more than 350 cells/μl in 1976 (48%) patients. TST was performed for 2922 (71%), of whom 657 (16%) were TST-positive [278 (13%) CD4 ≤ 350 vs. 379 (19%) CD4 > 350]. A total of 619 (15%) received IPT and 2806 (68%) received antiretroviral therapy. For patients with CD4 cell count 350 cells/μl or less who did not receive IPT, the incidence rate of TB was 1.79/100 person-years (pys) and TB/death was 3.89/100 pys. For patients with CD4 cell count more than 350 who did not receive IPT, the incidence rates of TB and TB/death were 0.57/100 and 1.49/100 pys for TST-negatives, and 1.05/100 and 1.64/100 pys for TST-unknowns. CONCLUSION: TB incidence was high among all patients who did not receive IPT, including those with CD4 cell count more than 350 cells/μl and negative or unknown TST results. TB preventive therapy should be provided to all people living with HIV in medium burden settings, regardless of CD4 cell count and TST status.

Original languageEnglish (US)
Pages (from-to)139-147
Number of pages9
JournalAIDS (London, England)
Volume34
Issue number1
DOIs
StatePublished - Jan 1 2020

Fingerprint

CD4 Lymphocyte Count
Tuberculin Test
Tuberculosis
Skin Tests
HIV
Isoniazid
Therapeutics
Incidence
Guidelines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV. / Chaisson, Lelia H.; Saraceni, Valeria; Cohn, Silvia; Seabrook, Dena; Cavalcante, Solange C.; Chaisson, Richard E.; Golub, Jonathan E.; Durovni, Betina.

In: AIDS (London, England), Vol. 34, No. 1, 01.01.2020, p. 139-147.

Research output: Contribution to journalArticle

Chaisson, Lelia H. ; Saraceni, Valeria ; Cohn, Silvia ; Seabrook, Dena ; Cavalcante, Solange C. ; Chaisson, Richard E. ; Golub, Jonathan E. ; Durovni, Betina. / CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV. In: AIDS (London, England). 2020 ; Vol. 34, No. 1. pp. 139-147.
@article{d8ad79e050414f8692daa70a1cddc030,
title = "CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV",
abstract = "OBJECTIVES: In 2018, Brazilian guidelines changed to recommend tuberculosis (TB) preventive therapy for all people with HIV and a CD4 cell count 350 cells/μl or less, but only for those with a positive tuberculin skin test (TST) if CD4 cell count is than 350 cells/μl. We determined the potential effectiveness of CD4-based guidelines for TB testing and preventive therapy. DESIGN: Secondary analysis of the stepped-wedge, cluster-randomized THRio trial for isoniazid preventive therapy (IPT). METHODS: We analyzed data from 4114 newly registered patients with HIV in 29 clinics followed until TB diagnosis, death, or administrative censoring. We compared incidence rates of TB and TB/death between CD4, TST, IPT, and antiretroviral therapy categories. RESULTS: Initial CD4 cell count was 350 cells/μl or less in 2138 (52{\%}) and more than 350 cells/μl in 1976 (48{\%}) patients. TST was performed for 2922 (71{\%}), of whom 657 (16{\%}) were TST-positive [278 (13{\%}) CD4 ≤ 350 vs. 379 (19{\%}) CD4 > 350]. A total of 619 (15{\%}) received IPT and 2806 (68{\%}) received antiretroviral therapy. For patients with CD4 cell count 350 cells/μl or less who did not receive IPT, the incidence rate of TB was 1.79/100 person-years (pys) and TB/death was 3.89/100 pys. For patients with CD4 cell count more than 350 who did not receive IPT, the incidence rates of TB and TB/death were 0.57/100 and 1.49/100 pys for TST-negatives, and 1.05/100 and 1.64/100 pys for TST-unknowns. CONCLUSION: TB incidence was high among all patients who did not receive IPT, including those with CD4 cell count more than 350 cells/μl and negative or unknown TST results. TB preventive therapy should be provided to all people living with HIV in medium burden settings, regardless of CD4 cell count and TST status.",
author = "Chaisson, {Lelia H.} and Valeria Saraceni and Silvia Cohn and Dena Seabrook and Cavalcante, {Solange C.} and Chaisson, {Richard E.} and Golub, {Jonathan E.} and Betina Durovni",
year = "2020",
month = "1",
day = "1",
doi = "10.1097/QAD.0000000000002398",
language = "English (US)",
volume = "34",
pages = "139--147",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV

AU - Chaisson, Lelia H.

AU - Saraceni, Valeria

AU - Cohn, Silvia

AU - Seabrook, Dena

AU - Cavalcante, Solange C.

AU - Chaisson, Richard E.

AU - Golub, Jonathan E.

AU - Durovni, Betina

PY - 2020/1/1

Y1 - 2020/1/1

N2 - OBJECTIVES: In 2018, Brazilian guidelines changed to recommend tuberculosis (TB) preventive therapy for all people with HIV and a CD4 cell count 350 cells/μl or less, but only for those with a positive tuberculin skin test (TST) if CD4 cell count is than 350 cells/μl. We determined the potential effectiveness of CD4-based guidelines for TB testing and preventive therapy. DESIGN: Secondary analysis of the stepped-wedge, cluster-randomized THRio trial for isoniazid preventive therapy (IPT). METHODS: We analyzed data from 4114 newly registered patients with HIV in 29 clinics followed until TB diagnosis, death, or administrative censoring. We compared incidence rates of TB and TB/death between CD4, TST, IPT, and antiretroviral therapy categories. RESULTS: Initial CD4 cell count was 350 cells/μl or less in 2138 (52%) and more than 350 cells/μl in 1976 (48%) patients. TST was performed for 2922 (71%), of whom 657 (16%) were TST-positive [278 (13%) CD4 ≤ 350 vs. 379 (19%) CD4 > 350]. A total of 619 (15%) received IPT and 2806 (68%) received antiretroviral therapy. For patients with CD4 cell count 350 cells/μl or less who did not receive IPT, the incidence rate of TB was 1.79/100 person-years (pys) and TB/death was 3.89/100 pys. For patients with CD4 cell count more than 350 who did not receive IPT, the incidence rates of TB and TB/death were 0.57/100 and 1.49/100 pys for TST-negatives, and 1.05/100 and 1.64/100 pys for TST-unknowns. CONCLUSION: TB incidence was high among all patients who did not receive IPT, including those with CD4 cell count more than 350 cells/μl and negative or unknown TST results. TB preventive therapy should be provided to all people living with HIV in medium burden settings, regardless of CD4 cell count and TST status.

AB - OBJECTIVES: In 2018, Brazilian guidelines changed to recommend tuberculosis (TB) preventive therapy for all people with HIV and a CD4 cell count 350 cells/μl or less, but only for those with a positive tuberculin skin test (TST) if CD4 cell count is than 350 cells/μl. We determined the potential effectiveness of CD4-based guidelines for TB testing and preventive therapy. DESIGN: Secondary analysis of the stepped-wedge, cluster-randomized THRio trial for isoniazid preventive therapy (IPT). METHODS: We analyzed data from 4114 newly registered patients with HIV in 29 clinics followed until TB diagnosis, death, or administrative censoring. We compared incidence rates of TB and TB/death between CD4, TST, IPT, and antiretroviral therapy categories. RESULTS: Initial CD4 cell count was 350 cells/μl or less in 2138 (52%) and more than 350 cells/μl in 1976 (48%) patients. TST was performed for 2922 (71%), of whom 657 (16%) were TST-positive [278 (13%) CD4 ≤ 350 vs. 379 (19%) CD4 > 350]. A total of 619 (15%) received IPT and 2806 (68%) received antiretroviral therapy. For patients with CD4 cell count 350 cells/μl or less who did not receive IPT, the incidence rate of TB was 1.79/100 person-years (pys) and TB/death was 3.89/100 pys. For patients with CD4 cell count more than 350 who did not receive IPT, the incidence rates of TB and TB/death were 0.57/100 and 1.49/100 pys for TST-negatives, and 1.05/100 and 1.64/100 pys for TST-unknowns. CONCLUSION: TB incidence was high among all patients who did not receive IPT, including those with CD4 cell count more than 350 cells/μl and negative or unknown TST results. TB preventive therapy should be provided to all people living with HIV in medium burden settings, regardless of CD4 cell count and TST status.

UR - http://www.scopus.com/inward/record.url?scp=85075962399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075962399&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000002398

DO - 10.1097/QAD.0000000000002398

M3 - Article

C2 - 31634189

AN - SCOPUS:85075962399

VL - 34

SP - 139

EP - 147

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 1

ER -